BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DNA 2.0, Inc. Announces The Launch Of PlanetGene - The First Online Repository Of Codon Optimized Human Genes Available For Purchase


10/19/2005 5:12:01 PM

MENLO PARK, Calif., Nov. 1 /PRNewswire/ -- DNA 2.0, Inc. (http://www.dnatwopointo.com/), a leader in custom gene synthesis and protein engineering, announced today the launch of PlanetGene(TM), the first comprehensive online gene catalog with an initial offering of over twenty-five thousand human genes commercially available for scientific research. Each gene has been codon optimized for expression in both bacterial and mammalian systems, allowing users to easily move between the two experimental systems. The genes have also been designed to avoid features that are frequently problematic in protein expression such as mRNA secondary structure, repetitive DNA elements and internal translation initiation sites. The PlanetGene online catalog of codon optimized human genes is easily accessed and searched on the basis of amino acid sequences, keywords, or Genbank accession numbers.

"Easy access to genes that are already codon optimized will drastically reduce the cost, time and resources to maintain a strong R&D pipeline," said Jeremy Minshull, PhD, president of DNA 2.0. "PlanetGene furthers DNA 2.0's aim to reduce the cost and complexity of outsourcing routine molecular biology. By closing the gap between sequences in databases and physically useable genes, it will enable corporate and academic research scientists to focus their resources fully on their critical research rather than on creating the tools they need."

PlanetGene will transform the efficiency and effectiveness of biological research from basic science to drug discovery, and marks a milestone in DNA 2.0's goal of industrializing molecular biology. Providing immediate access to synthetic human genes designed for use in the two major expression platforms marks a new phase in the company's drive to empower researchers in the pharmaceutical industry and beyond.

PlanetGene combines the efficiency of the DNA-2-Go(TM) gene synthesis technology, developed by DNA 2.0, with powerful Protein-2-DNA(TM) gene design algorithms. The result is affordable high quality optimized genes available to the entire research community. Benefits to researchers are:

-- Speed - Even an experienced researcher can take several months or even longer to codon optimize and synthesize an average 1000 base pair human gene. From order to delivery, PlanetGene reduces that time to 2 weeks.

-- Cost - to have an average 1000 base pair human gene custom synthesized commercially costs around $2,500. Codon optimized genes from PlanetGene will start at about $100.

-- Reliability - DNA 2.0 is a published leader in the area of codon optimization for heterologous protein expression. Genes optimized using the company's extensively tested Protein-2-DNA gene design have shown consistently good expression in E. Coli and mammalian systems. The genes offered through PlanetGene have been redesigned to greatly improve expression, but the protein sequence is completely unchanged from the original human sequence. The integrity of each gene is verified by double stranded DNA sequencing to ensure 100% accuracy.

DNA 2.0 is the developer of two platform technologies, the DNA-2-Go gene synthesis process and DeNovo Genes(TM), a protein engineering and sequence optimization technology. The firm's charter is to exploit the synergy between a highly efficient gene synthesis process and new protein optimization technologies. Following the initial launch, DNA 2.0 will continue building the PlanetGene repository by adding codon optimized human splicing variants. PlanetGene will also be expanded to offer codon optimized genes from other organisms. PlanetGene can be accessed through the DNA2.0 website (http://www.dnatwopointo.com/) or directly at http://www.planetgene.com/.

About DNA 2.0, Inc.

DNA 2.0 is applying its DNA-2-Go(TM) custom genes synthesis process and its DeNovo Genes(TM) platform technology to design and produce information-rich gene variants. These gene variants are synthesized individually and then tested for functional activity. The data is analyzed and mapped as a mega dimensional projection of the correlated sequence-function space. The DeNovo Genes technology is uniquely suited to engineering proteins for commercial applications such as industrial biocatalysis and healthcare products including therapeutic proteins and diagnostic reagents. A basic version of Protein-2-DNA(TM) software can be downloaded free from http://www.protein2dna.com/. For more information please visit http://www.dnatwopointo.com/ or email info@dnatwopointo.com.

DNA 2.0, Inc.

CONTACT: DNA 2.0, Inc., corpcom@dnatwopointo.com; or Kaye McKinzie ofAperio Healthcare, +1-415-927-7365, or kaye@aperiohc.com, for DNA 2.0, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES